Sara Rollinson

Sara Rollinson

Auto-generated profile, based on publicly available information

Sara Rollinson

Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2013 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
DMDavid Ma Mann
David Ma Mann
SRSara Rollinson
Sara Rollinson
ARAndrew Robinson
Andrew Robinson
JCJanis Bennion Callister
Janis Bennion Callister
JTJennifer C Thompson
Jennifer C Thompson
SPStuart Pickering-Brown
Stuart Pickering-Brown
Cases of Frontotemporal Lobar Degeneration (FTLD) and Motor Neurone Disease (MND) associated with expansions in C9ORF72 gene are characterised pathologically by the presence of TDP-43 negative, but p62 positive, inclusions in granule cells of the cerebellum and in cells of dentate gyrus and area CA4 of the hippocampus.

20 June 2014 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
YDYvonne S Davidson
Yvonne S Davidson
HBHolly Barker
Holly Barker
ARAndrew Robinson
Andrew Robinson
JTJennifer C Thompson
Jennifer C Thompson
JHJenny Harris
Jenny Harris
DMDavid M Mann
David M Mann
A hexanucleotide (GGGGCC) expansion in C9ORF72 gene is the most common genetic change seen in familial Frontotemporal Lobar Degeneration (FTLD) and familial Motor Neurone Disease (MND). Pathologically, expansion bearers show characteristic p62 positive, TDP-43 negative inclusion bodies within cerebellar and hippocampal neurons which also contain dipeptide repeat proteins (DPR) formed from sense and antisense RAN (repeat associated non ATG-initiated) translation of the expanded repeat region itself. ‘Inappropriate’ formation, and aggregation, of DPR might therefore confer neurotoxicity and influence clinical phenotype. Consequently, we compared the topographic brain distribution of DPR in 8 patients with Frontotemporal dementia (FTD), 6 with FTD + MND and 7 with MND alone (all 21 patients bearing expansions in C9ORF72) using a polyclonal antibody to poly-GA, and related this to the extent of TDP-43 pathology in key regions of cerebral cortex and hippocampus. There were no significant differences in either the pattern or severity of brain distribution of DPR between FTD, FTD + MND and MND groups, nor was there any relationship between the distribution of DPR and TDP-43 pathologies in expansion bearers. Likewise, there were no significant differences in the extent of TDP-43 pathology between FTLD patients bearing an expansion in C9ORF72 and non-bearers of the expansion. There were no association between the extent of DPR pathology and TMEM106B or APOE genotypes. However, there was a negative correlation between the extent of DPR pathology and age at onset. Present findings therefore suggest that although the presence and topographic distribution of DPR may be of diagnostic relevance in patients bearing expansion in C9ORF72 this has no bearing on the determination of clinical phenotype. Because TDP-43 pathologies are similar in bearers and non-bearers of the expansion, the expansion may act as a major genetic risk factor for FTLD and MND by rendering the brain highly vulnerable to those very same factors which generate FTLD and MND in sporadic disease.

1 August 2003
Verified
Journal Article
Closed access
KSKathryn Sibley
Kathryn Sibley
SRSara Rollinson
Sara Rollinson
JAJames Allan
James Allan
ASAlexandra G Smith
Alexandra G Smith
GLGraham R Law
Graham R Law
GMGareth John Morgan
Gareth John Morgan

1 February 2007 in Leukemia Research
Verified
Journal Article
Closed access
SRSara Rollinson
Sara Rollinson
ASAlexandra G. Smith
Alexandra G. Smith
JAJames M. Allan
James M. Allan
PAPeter J. Adamson
Peter J. Adamson
KSKathryn Scott
Kathryn Scott
GMGareth John Morgan
Gareth John Morgan

1 August 2003
Verified
Journal Article
Closed access
LWLisa J Worrillow
Lisa J Worrillow
LTLois B Travis
Lois B Travis
ASAlexandra G Smith
Alexandra G Smith
SRSara Rollinson
Sara Rollinson
ASAndrew J Smith
Andrew J Smith
JAJames Allan
James Allan

1 January 2006 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SRSara Rollinson
Sara Rollinson
HKHeather Kesby
Heather Kesby
GMGareth John Morgan
Gareth John Morgan
The MRE11-RAD50-NBS1 tri-complex is involved in the cellular response to DNA double strand breaks, detecting DNA damage, activating cell cycle checkpoints and apoptosis. Defects in members of the tri-complex are linked to increased chromosomal instability and in lymphoma predisposition. Using genotyping data from six intronic or gene flanking variants in MRE11, five in NBS1 and six in RAD50 in 461 non-Hodgkin's lymphoma cases and 461 age, sex matched controls, Phase 2.1 was used to impute haplotypes for each of these genes. It was observed that the average variant density (12 kb) was dense enough to capture the majority of genetic variation for each locus examined, encoded by four or five common haplotypes. There were no significant differences in allele or genotype frequency, global haplotype distribution between the cases and control, nor effect for individual haplotypes when analysed by unconditional logistic regression for either RAD50 or NBS1. A protective effect against follicular lymphoma was seen for the MRE11 rs601341 variant, the homozygous T allele being associated with an odds ratio (OR) of 0.50, 95% confidence interval (95% CI) 0.26 – 0.97, while a protective effect was seen for the MRE11 haplotype GCTCA (OR 0.72, 95% CI 0.53 – 0.97) for diffuse large B-cell lymphoma. While reproduction of this data in other datasets is indicated, the results are indicative for a role for MRE11 in non-Hodgkin's lymphoma.